Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart patients could go home in 24 hours after valve procedure

NCT ID NCT05758909

Knowledge-focused Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people who get a new heart valve through a tube in their leg (TAVI) can safely go home just 24 hours later. Researchers will track 585 patients for complications like stroke, heart attack, or need for a pacemaker. The goal is to see if early discharge is both safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that early discharge after TAVI is safe, leading to shorter hospital stays and faster recovery for patients.
What could go wrong
This is an observational study, not a randomized trial, so results may not prove cause and effect. Complications like stroke or heart issues could still occur after early discharge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 585 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing scheduled transfemoral TAVI implantation, performed on an outpatient basis

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who meet all of the following conditions will be included: * Patients ≥ 18 years undergoing transfemoral TAVI implantation scheduled, performed on an outpatient basis. * Patients with percutaneous implant. * Patients undergoing the procedure under superficial sedation or Local anesthesia. * Patients with baseline narrow QRS that does not change after implantation, or definitive pacemaker carrier. * Patients who have signed the informed consent. Exclusion Criteria: Patients who do not meet any of the following conditions: * Patients with a wide QRS (greater than or equal to 120 msec) at baseline, with the except for patients with permanent pacemakers. * Hospitalized patients undergoing urgent TAVI implantation. * Patients with access other than percutaneous transfemoral.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aortic Valve Disease aortic valve disorder aortic valve stenosis heart valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aortic valve disease Aortic valve stenosis Heart valve diseases

Contacts and locations

Locations

  • Hospital Clinico San Carlos

    Aravaca, 28040, Spain

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, 15706, Spain

  • Hospital General Universitario Dr. Balmis

    Alicante, 03010, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, 29010, Spain

  • Hospital Universitari Germans Trias I Pujol

    Badalona, 08916, Spain

  • Hospital Universitari Vall Hebron

    Barcelona, 08035, Spain

  • Hospital Universitari i Politècnic la Fe

    Valencia, 46026, Spain

  • Hospital Universitario A Coruña

    A Coruña, 15006, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, 33011, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41013, Spain

  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, 08907, Spain

  • Hospital Universitario de Navarra

    Pamplona, 31008, Spain

  • Hospital de Santa Creu I Sant Pau

    Barcelona, 08025, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.